Mitsubishi Tanabe Pharma Holdings America, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$23.9M
Doctors Paid
5,282
Transactions
21,417
2024 Total
$5.2M
Payment Breakdown by Category
Research$21.7M (90.6%)
Consulting$974,180 (4.1%)
Food & Beverage$365,251 (1.5%)
Travel$152,877 (0.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $21.7M | 2,270 | 90.6% |
| Consulting Fee | $974,180 | 601 | 4.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $412,922 | 172 | 1.7% |
| Food and Beverage | $365,251 | 17,006 | 1.5% |
| Grant | $202,150 | 23 | 0.8% |
| Travel and Lodging | $152,877 | 567 | 0.6% |
| Space rental or facility fees (teaching hospital only) | $96,500 | 28 | 0.4% |
| Honoraria | $31,155 | 10 | 0.1% |
| Education | $10,437 | 740 | 0.0% |
Payments by Type
Research
$21.7M
2,270 transactions
General
$2.2M
19,147 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| RADICAVA (EDAVARONE) FINDINGS IN BIOMARKERS FROM ALS (REFINE-ALS) | $3.4M | 0 | 89 |
| Radicava (Edaravone) Findings in Biomarkers From ALS (REFINE-ALS) | $3.1M | 0 | 2 |
| RADICAVA EDAVARONE FINDINGS IN BIOMARKERS FROM ALS REFINE-ALS | $2.6M | 0 | 23 |
| A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF MT-3921 IN SUBJECTS WITH ACUTE TRAUMATIC CERVICAL SPINAL CORD INJURY | $1.6M | 0 | 172 |
| A PHASE 3B, MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY TO EVALUATE EFFICACY AND SAFETY OF ORAL EDARAVONE ADMINISTERED FOR A PERIOD OF 48 WEEKS IN SUBJECTS WITH AMYOTROPHIC LATERAL SCLEROSIS (ALS) | $811,408 | 0 | 398 |
| A PHASE 3, MULTICENTER, OPEN-LABEL, LONG-TERM, EXTENSION STUDY TO EVALUATE SAFETY AND TOLERABILITY OF ORAL DERSIMELAGON (MT-7117) IN SUBJECTS WITH ERYTHROPOIETIC PROTOPORPHYRIA (EPP) OR X-LINKED PROTOPORPHYRIA (XLP) | $810,641 | 0 | 534 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE EFFICACY, SAFETY, AND TOLERABILITY OFMT-7117IN ADULTS AND ADOLESCENTS WITH ERYTHROPOIETIC PROTOPORPHYRIA OR X-LINKED PROTOPORPHYRIA | $759,614 | 0 | 216 |
| HOME-BASED REMOTE DIGITAL MONITORING TO ASSESS ALS PROGRESSION (TRACK ALS) | $702,118 | 0 | 5 |
| CTA FEASIBILITY AND SENSITIVITY OF A SYMPTOM MONITORING APPLICATION IN REAL TIME SMART IN ALS | $625,239 | 0 | 1 |
| A PHASE 3B, MULTICENTER, RANDOMIZED, DOUBLE-BLIND EXTENSION STUDY TO EVALUATE THE CONTINUED EFFICACY AND SAFETY OF ORAL EDARAVONE ADMINISTERED FOR AN ADDITIONAL PERIOD OF UP TO 48 WEEKS FOLLOWING STUDY MT-1186-A02 IN SUBJECTS WITH AMYOTROPHIC LATERAL SCLEROSIS (ALS) | $565,021 | 0 | 277 |
| HOME-BASED SPIROMETRY THROUGH TELEMEDICINE IN AMYOTROPIC LATERAL SCLEROSIS | $525,194 | 0 | 24 |
| REFINE-ALS (BIOMARKER STUDY) | $518,152 | 0 | 9 |
| NATURAL HISTORY REPOSITORY OF ALS/MND | $500,000 | 0 | 1 |
| A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE EFFICACY, SAFETY, AND TOLERABILITY OF MT-7117 IN SUBJECTS WITH DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS | $471,251 | 0 | 257 |
| A PROSPECTIVE MULTICENTER, LONGITUDINAL, OBSERVATIONAL COHORT STUDY TO ASSESS THE MEASUREMENT PROPERTIES OF CLINICAL OUTCOMES ASSESSMENTS IN PATIENTS WITH TRAUMATIC LOW CERVICAL SPINAL CORD INJURY | $406,878 | 0 | 36 |
| DRUG TARGET DISCOVERY FOR ASD | $343,715 | 0 | 2 |
| Drug Target Discovery for ASD | $309,344 | 0 | 1 |
| Home-based Remote Digital Monitoring to Assess ALS Progression (Track ALS) | $303,389 | 0 | 2 |
| Biomarkers of progressive systemic sclerosis associated interstitial lung disease (SSc-ILD) | $262,358 | 0 | 1 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE EFFICACY, SAFETY, AND TOLERABILITY OF MT-7117 IN ADULTS AND ADOLESCENTS WITH ERYTHROPOIETIC PROTOPORPHYRIA OR X-LINKED PROTOPORPHYRIA | $255,969 | 0 | 34 |
| OXIDATIVE MARKERS AND EFFICACY IN ALS/MND PHENOTYPES TREATED WITH EDARAVONE | $247,010 | 0 | 3 |
| FEASIBILITY AND SENSITIVITY OF A SYMPTOM MONITORING APPLICATION IN REAL TIME (SMART) IN ALS | $214,884 | 0 | 1 |
| CTA: FEASIBILITY AND SENSITIVITY OF A SYMPTOM MONITORING APPLICATION IN REAL TIME (SMART) IN ALS | $208,947 | 0 | 1 |
| A PHASE 3, MULTI-CENTER, OPEN-LABEL, SAFETY EXTENSION STUDY OF ORAL EDARAVONE ADMINISTERED OVER 96 WEEKS IN SUBJECTS WITH AMYOTROPHIC LATERAL SCLEROSIS (ALS) | $201,499 | 0 | 134 |
| ANALYSIS OF HUMAN ALS TISSUES AND REGISTRY OF ALS PATIENTS | $178,596 | 0 | 1 |
| BIOMARKERS OF PROGRESSIVE SYSTEMIC SCLEROSIS ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD) | $174,906 | 0 | 2 |
| Effect Of Multidisciplinary And Traditional Non-Multidisciplinary Care Paradigms On Healthcare Outcomes, Quality Of Life And Cost | $160,501 | 0 | 1 |
| EFFECT OF MULTIDISCIPLINARY AND TRADITIONAL NON-MULTIDISCIPLINARY CARE PARADIGMS ON HEALTHCARE OUTCOMES, QUALITY OF LIFE AND COST | $160,501 | 0 | 4 |
| BNI-ALS-005 | $146,041 | 0 | 1 |
| CHICAGO ALS BIOMARKER STUDY | $138,908 | 0 | 3 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2023 |
|---|---|---|---|---|
| Ghazala Hayat, Md, MD | Clinical Neurophysiology | Saint Louis, MO | $123,022 | $0 |
| Carlayne Jackson, M.d, M.D | Neuromuscular Medicine | San Antonio, TX | $94,933 | $0 |
| Jonathan Katz, M.d, M.D | Anatomic Pathology & Clinical Pathology | San Francisco, CA | $69,997 | $0 |
| Benjamin Brooks, Md, MD | Internal Medicine | Charlotte, NC | $65,507 | $0 |
| Jeffrey Rosenfeld, Md, MD | Clinical Neurophysiology | Fresno, CA | $65,369 | $0 |
| Said Beydoun, M.d, M.D | Neurology | Los Angeles, CA | $63,394 | $0 |
| Gary Pattee, M.d, M.D | Neurology | Lincoln, NE | $49,957 | $0 |
| Martina Wiedau, Md, MD | Neurology | Los Angeles, CA | $44,967 | $0 |
| Jeremy Shefner, M.d, M.D | Neurology | Phoenix, AZ | $43,173 | $0 |
| David Walk, Md, MD | Neurology | Minneapolis, MN | $37,542 | $0 |
| Terry Heiman-Patterson, Md, MD | Neurology | Philadelphia, PA | $36,776 | $0 |
| Prof. Erik Pioro, Md, Phd, MD, PHD | Neuromuscular Medicine | Chicago, IL | $36,420 | $0 |
| Dr. Tuan Vu, Md, MD | Neurology | Tampa, FL | $33,872 | $0 |
| Tomas Holmlund, M.d, M.D | Neurology | Amherst, NY | $32,764 | $0 |
| Stanley Appel, M.d, M.D | Neurology | Houston, TX | $28,766 | $0 |
| Leonard Milstone, Md, MD | Dermatology | New Haven, CT | $27,733 | $0 |
| Dr. Raghav Govindarajan, Md, MD | Neurology | O Fallon, IL | $25,228 | $0 |
| Bjorn Oskarsson, Md, MD | Neurology | Jacksonville, FL | $23,181 | $0 |
| Alberto Espay, Md, MD | Neurology | Cincinnati, OH | $22,850 | $0 |
| Tulio Bertorini, Md, MD | Neurology | Memphis, TN | $17,086 | $0 |
| Kourosh Rezania | Neurology | Chicago, IL | $16,157 | $0 |
| Dr. Merit Cudkowicz, Md, MD | Neurology | Boston, MA | $16,095 | $0 |
| John Novak, M.d, M.D | Neurology | Westerville, OH | $15,848 | $0 |
| Rajesh Pahwa, M.d, M.D | Neurology | Kansas City, KS | $15,125 | $0 |
| Dr. E Dorsey, M.d, M.D | Neurology | New York, NY | $15,035 | $0 |
Ad
Top Products
- RADICAVA $8.2M
- Radicava $1.5M
Associated Products (5)
- RADICAVA $8.2M
- Radicava $1.5M
- RADICAVA ORS $72,338
- EXSERVAN $23,156
- Radicava ORS $18,824
Payment Categories
- Food & Beverage $365,251
- Consulting $974,180
- Travel & Lodging $152,877
- Research $21.7M
About Mitsubishi Tanabe Pharma Holdings America, Inc.
Mitsubishi Tanabe Pharma Holdings America, Inc. has made $23.9M in payments to 5,282 healthcare providers, recorded across 21,417 transactions in the CMS Open Payments database. In 2024, the company paid $5.2M. The top product by payment volume is RADICAVA ($8.2M).
Payments were distributed across 124 medical specialties. The top specialty by payment amount is Neurology ($1.0M to 2,572 doctors).
Payment categories include: Food & Beverage ($365,251), Consulting ($974,180), Research ($21.7M), Travel & Lodging ($152,877).
Mitsubishi Tanabe Pharma Holdings America, Inc. is associated with 5 products in the CMS Open Payments database, including RADICAVA, Radicava, and RADICAVA ORS.